This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kazuyo Naito, MD, PhD; Neal R. Pellis, PhD; Barry D. Kahan, MD, PhD

Arch Surg. 1986;121(12):1415-1420.

Abstract
• A methylcholanthrene-induced fibrosarcoma model in C3H/HeJ mice demonstrated that combined chemoimmunotherapy, including partially purified, 1-butanol—extracted, tumor-specific transplantation antigen (1 µg), cyclophosphamide (20 mg/kg), and continuous Intrasplenic (IS) or intravenous (IV) infusion of purified human interleukin-2 (IL-2) (120 U/d) reduced the outgrowth of 4-mm established tumors, while IL-2 alone only modestly decreased tumor growth. For tumors larger than 1 cm, only the triple regimen with IS IL-2 significantly inhibited tumor growth, whereas IL-2 alone or the triple regimen with IV IL-2 failed to retard tumor growth. Furthermore, the first regimen significantly decreased pulmonary metastases after primary tumor resection. The Lyt-2⁺ phenotype predominated in the effector population of animals treated with this regimen, while L3T4⁺ cells predominated in those treated with the triple regimen that included IV IL-2. Thus, continuous IS IL-2 administration potentiates the efficacy of antigen-specific chemoimmunotherapy.

(Arch Surg 1986;121:1415-1420)

Author Affiliations
From the Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston.

Footnotes
Accepted for publication Aug 13, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 12, 1986.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?